Janssen to Discontinue Hepatitis C Development Program

Food and Healthcare Press Releases Monday September 11, 2017 12:44
CORK, Ireland--11 Sep--PRNewswire/InfoQuest
  • Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B

Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter. This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

(Logo: http://photos.prnewswire.com/prnh/20140324/NY88746LOGO )

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists. Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally," said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen. "At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients."

Janssen pioneered the advancement of the first innovations in hepatitis C for nearly a decade when it co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus.[1] In collaboration with Medivir AB, Janssen subsequently developed and launched the second generation protease inhibitor OLYSIO(R) (simeprevir),[2] which is approved in countries around the world.

Today, people living with hepatitis C have a much more diverse range of therapies available following a wave of innovative treatments securing approval. For most, the standard of care for hepatitis C therapy has a duration of 8-12 weeks offering a cure to around 92-100% of people treated.[3]

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at http://www.janssen.com and follow us at @JanssenGlobal.


1. Janssen. INCIVO(R) Approved in Europe Offering High Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard of Care. Available at: https://www.jnj.com/media-center/press-releases/incivo-telaprevir-approved-in-europe-offering-higher-cure-rates-for-genotype-1-chronic-hepatitis-c-compared-to-standard-treatment Last accessed: September 2017.

2. Janssen. OLYSIO(TM) (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C. Available at: https://www.jnj.com/media-center/press-releases/olysio-simeprevir-receives-fda-approval-for-combination-treatment-of-chronic-hepatitis-c Last accessed: September 2017.

3. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology. 2017: 66(1):153-194.
Source: Janssen

Latest Press Release

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their...

FDI Global Survey Shows Children are not Getting Dental Check-ups Early Enough

On the occasion of World Oral Health Day, FDI World Dental Federation asked parents around the world how they cared for their children's oral health growing up and the responses suggest room for improvement. Maintaining a healthy mouth is crucial to...

Texas Cardiac Arrhythmia Institute at St. David#s Medical Center draws cardiac experts from across the globe for EPLive 2018

On March 1 and 2, 2018, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center hosted its fourth international symposium on complex arrhythmias, EPLive 2018. Nearly 200 leaders in the field of electrophysiology (EP) from Europe, Asia...

Johnson Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan,...

Biotherm Hosts the First Biotherm Healing Summit

Biotherm hosted the first "Biotherm Healing Summit" on March 7. A symposium on the theme of skin & healing, focusing on major research that has evidenced the link between micro-organisms and skin health. Unveiling Life PlanktonTM, the healing...

Related Topics